SGLT2 inhibitors: diabetes drugs that turned into organ protectors

Few drug classes have had a second act like this one. SGLT2 inhibitors — empagliflozin, dapagliflozin, canagliflozin — were designed to lower blood sugar by making the kidney dump glucose into the urine. On that job alone they are unremarkable: the glucose-lowering is modest. What made them one of the most consequential cardiometabolic advances of the last decade is what the outcome trials found by accident while checking whether the drugs were safe for the heart.

They were more than safe. In EMPA-REG OUTCOME, empagliflozin didn’t just avoid harm in high-risk type 2 diabetes — it reduced cardiovascular death and hospitalization for heart failure, and the curves separated within months, far too fast to be explained by better sugar control. That surprise reframed the entire class and launched a wave of trials that pulled these drugs out of the diabetes clinic and into cardiology and nephrology.

What the evidence shows

The evidence here is genuinely grade-A, built on large, well-run randomized trials with hard endpoints — not surrogate markers.

• Heart failure. In DAPA-HF, dapagliflozin reduced worsening heart failure and cardiovascular death in people with reduced ejection fraction, and — critically — the benefit held whether or not the patient had diabetes. That’s the finding that turned an antidiabetic drug into a first-line heart-failure medication now written into cardiology guidelines.
• Chronic kidney disease. In DAPA-CKD, dapagliflozin slowed the decline in kidney function and reduced progression to kidney failure and death, again with or without type 2 diabetes. CREDENCE had shown similar renal protection with canagliflozin in diabetic kidney disease. For a field where almost nothing new had slowed CKD in decades, this was a real advance.

The through-line is that the organ protection appears to be partly independent of glucose lowering — likely involving effects on kidney pressure, fluid balance, and cardiac energetics. You don’t need to be diabetic to benefit, which is why the label and the use case kept expanding.

The adult context

None of this makes SGLT2 inhibitors a general-wellness drug, and they carry side effects worth understanding plainly.

• Genital mycotic infections (yeast infections in men and women) are the most common adverse effect, a direct consequence of spilling sugar into the urine. They’re usually mild and easily treated, but they’re common enough that they’re part of the conversation.
• Euglycemic diabetic ketoacidosis is rare but important because it can occur with near-normal blood glucose, which delays recognition. Risk rises around surgery, acute illness, fasting, very low-carbohydrate intake, or heavy alcohol use — situations where the drug is often paused. This is an FDA-labeled warning, and it’s one of the main reasons this belongs in a monitored relationship rather than a self-directed stack.
• Volume depletion and dehydration can occur, especially in older adults or those on diuretics.

For the right person — heart failure, chronic kidney disease with protein in the urine, or type 2 diabetes with cardiovascular risk — the benefit is large and well-evidenced, and guidelines increasingly recommend these drugs regardless of glucose level. If you’re metabolically healthy with none of those conditions, this isn’t your tier; there’s no evidence it makes a healthy person healthier. The honest bottom line: a genuinely important class with hard-outcome data behind it, whose value and whose risks are both specific enough that they belong in a clinician conversation, not a supplement aisle.